Both in Pharmaceuticals
Cytokinetics vs Protagonist Therapeutics
Over the past year CYTK returned +21.8% and PTGX returned +116.4%; their daily moves had a correlation of 0.25.
CYTK +21.8% PTGX +116.4%Growth of $1, one year, split-adjusted
| Metric | CYTK | PTGX |
|---|---|---|
| Price | $65.64 | $140.97 |
| Market cap | $9.13B | $9.12B |
| Today | −0.79% | −1.03% |
| 1 month | −8.9% | −2.3% |
| 6 months | +4.2% | +41.2% |
| Year to date | +3.3% | +61.4% |
| 1 year | +30.2% | +109.1% |
| Revenue growth (YoY) | −57.1% | +3749.2% |
| Gross margin | 90.5% | 100.0% |
| Net margin | −694.4% | 76.3% |
| P/E (TTM) | — | 110.0× |
| Price / sales | 134.9× | 32.3× |
| Net cash | $18.6M | $782.6M |
| Dividend yield | — | — |
| Volatility (60d) | 33.7% | 40.1% |
| Short % of float | 14.4% | 13.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).